Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stem Cell Research -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (31)	1/22/2004 9:25:56 PM
From: SnowShredder	Read Replies (2) \| Respond to of 495

Just Parking...SS >>>>>>>>> MacroPore Biosurgery Awarded SBIR Grant from the NIH MacroPore Biosurgery Awarded SBIR Grant from the NIH to Study the Use of Adipose-Derived Regenerative Cells for Treating Heart Attack San Diego, CA, January 15, 2004 - MacroPore Biosurgery, Inc. (Frankfurt Stock Exchange: XMP) (MacroPore) announced today it has been awarded a Fast Track Phase I/II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to study the role of adipose-derived regenerative cells in treating myocardial infarction (heart attack). This research will be conducted in collaboration with W. Robb MacLellan M.D. at the David Geffen School of Medicine at the University of California, Los Angeles (U.C.L.A.). MacroPore and its collaborators have shown that adipose tissue is a rich source of autologous regenerative cells, which contain adult stem cells. The SBIR studies are designed to evaluate the capacity of adipose-derived regenerative cells to improve revascularization and regenerate damaged myocardial tissue following a heart attack. By using adipose tissue as a cell source, MacroPore intends to demonstrate that it can obtain therapeutically relevant quantities of regenerative-capable cells in real-time. 'The limited ability of the adult heart to regenerate itself after an injury such as heart attack frequently leads to heart failure or other complications,' said Dr. MacLellan. 'The research performed to date at MacroPore suggests that regenerative cells purified from adipose tissue may represent a clinically useful source of cells to promote myocardial regeneration in patients immediately after a heart attack. This grant will allow us to continue our collaboration with MacroPore and further accelerate this research.' 'MacroPore has gained a significant understanding of the potential clinical applications for adipose-derived regenerative cells from our preclinical studies,' said Christopher J. Calhoun, President and Chief Executive Officer of MacroPore. 'The receipt of this grant will provide funding to help advance our development program.' About MacroPore Biosurgery, Inc. MacroPore Biosurgery (Frankfurt: XMP) (MacroPore) is the global leader in the discovery and development of regenerative medicine technologies and therapies. We are committed to improving the practice of medicine by creating innovative products that address two important segments of medicine: spine and orthopedic repair and cardiovascular disease. Our surgical implants, which represent one of the latest advancements in spine and orthopedic medicine, are manufactured at MacroPore and marketed exclusively through Medtronic Sofamor Danek. Additionally, we are developing a cell-based therapy to regenerate damaged heart muscle resulting from myocardial infarction. The approach will be based on a cell-therapy system, currently under development, capable of isolating regenerative cells from adipose tissue. For further information please visit our web site macropore.com . Kontakt: Tom Baker Media/U.S. Investors Tel. +1-858-458-0900 tbaker@macropore.com Stefanie Bacher European Investors Tel. +1-858-362-0365 sbacher@macropore.com Cautionary Statement Regarding Forward-Looking Statements This press release may include forward-looking statements regarding events and trends which may affect MacroPore Biosurgery's future operating results and financial position. Such statements are subject to risks and uncertainties that could cause MacroPore Biosurgery's actual results and financial position to differ materially. These risks and uncertainties are described (under the heading 'Risk Factors') in our 2002 Annual Report which is available on our web site. MacroPore Biosurgery assumes no responsibility to publicly release the results of any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.